Selegiline in ADHD adults: Plasma monoamines and monoamine metabolites

Neuropsychopharmacology

Volumn 16, Issue 4, 1997, Pages 276-284

  Ernst, Monique ^a,c   Liebenauer, Laura L ^a   Tebeka, Daniel ^a   Jons, Peter H ^a   Eisenhofer, Graeme ^b   Murphy, Dennis L ^a   Zametkin, Alan J ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

ADHD; Attention; Hyperactivity; MAOI; Monoamine metabolites; Plasma monoamines; Selegiline

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; ADRENALIN; DOPAMINE; HOMOVANILLIC ACID; METADRENALIN; MONOAMINE; NORADRENALIN; PLACEBO; SELEGILINE;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERACTIVITY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTONINERGIC SYSTEM; SINGLE BLIND PROCEDURE;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIOGENIC MONOAMINES; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MONOAMINE OXIDASE INHIBITORS; NOREPINEPHRINE; PSYCHOMOTOR PERFORMANCE; SELEGILINE; SEROTONIN;

EID: 0030903731     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(96)00243-6     Document Type: Article

References (40)

1. American Psychiatric Association (1987): Diagnostic and Statistical Manual of Mental Disorders, ed 3, rev. Washington, DC: American Psychiatric Press
2. Aston-Jones G, Foote SJ, Bloom FE (1984): Anatomy and physiology of locus coeruleus neurons: Functional implications. In Zeigler MG, Lake CR (eds), Norepinephrine: Clinical aspects. Baltimore, Williams & Wilkins, pp 113-125
3. Castellanos FX, Elia J, Kruesi MJP, Gulotta CS, Mefford IN, Potter WZ, Ritchie GF, Rapoport JL (1994): Cerebrospinal fluid monoamine metabolites in ADHD boys. Psychiatr Res 52:205-316
4. Castellanos FX, Elia J, Kruesi MJP, Marsh WL, Gulotta CS, Potter WZ, Ritchie GF, Hamburger SD, Rapoport JL (1996): Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with Attention-Deficit/Hyperactivity Disorder. Neuropsychopharmacology 14:125-137
5. Celada P, Sarriias MJ, Artigas F (1990): Serotonin and 5-hydroxy-indoleacetic acid in plasma: Potential use as peripheral measures of MAO-A activity. J Neural Transm 32:149-154
6. Conners CK (1969): A teacher rating scale for use in drug studies with children. Am J Psychiatr 126:152-156
7. Dienstbier RA (1989): Arousal and physiological toughness: Implications for mental and physical health, Psychol Rev 96:4-100
8. Donnelly M, Rapoport JL, Potter WZ, Oliver J, Keysor CS, Murphy DL (1989): Fenfluramine and dextroamphetamine treatment of childhood hyperactivity: Clinical and biochemical findings. Arch Gen Psychiatr 46:205-212
9. Eisenhofer G, Goldstein DS, Stull R, Keiser HR, Sunderland T, Murphy DL, Kopin IJ (1986): Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clin Chem 32:2030-2033
10. Endicott J, Spitzer RL (1978): A diagnostic interview: The schedule for affective disorders and schizophrenia. Arch Gen Psychiatr 35:837-844
11. Ernst M, Liebenauer LL, Jons PH, Tebeka D, Cohen RM, Zametkin AJ (1996): Selegiline in adults with Attention Deficit/Hyperactivity Disorder: Clinical efficacy and safety. Psychopharm Bull 32:327-334
12. Fuller RW (1968): Influence of substrate in the inhibition of rat liver and brain monoamine oxidase. Arch Intern Pharmacodyn Ther 174:32-37
13. Goridis C, Neff NH (1971): Evidence for a specific monoamine oxidase B associated with sympathetic nerves. Neuropharmacology 10:557-564
14. Heinonen EH, Myllyla V, Sotaniemi K, Lammintausta R, Salonen JS, Anttila M, Savijarvi M, Kotila M, Rinne UK (1989): Pharmacokinetics and metabolism of selegiline. Acta Neurol Scand 126:93-99
15. Irwin M, Elendick K, McGloskay K, Freedman DX (1981): Tryptophan metabolism in children with attention deficit disorder. Am J Psychiatr 138:1082-1085
16. Johnston JP (1968): Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17:1285-1297
17. Knoll J (1989): The pharmacology of selegiline ((-) deprenyl). New aspects. Acta Neurol Scand 126:83-91
18. Kopin IJ (1985): Catecholamine metabolism: Basic aspects and clinical significance. Pharm Rev 37:334-364
19. Lenders JWM, Eisenhofer G, Armando I, Keiser HR, Goldstein DS, Kopin LJ (1993): Determination of metanephrines in plasma by liquid chromatography with electrochemical detection. Clin Chem 39:97-103
20. McCabe BJ (1986): Dietary tyramine and other pressor amines in MAOI regimens: A review. J Am Diet Assoc 86:1059-1064
21. McCracken JT (1990): A two-part model of stimulant action on attention-deficit hyperactivity disorder in children. J Neuropsychiatr Clin Neurosci 3:201-209
22. Mefford IN, Potter WZ (1989): A neuroanatomical and biochemical basis for attention deficit disorder with hyperactivity in children: A defect in tonic adrenaline mediated inhibition of locus coeruleus stimulation. Med Hypotheses 29:33-42
23. Murphy DL, Pickar D, Jimerson D, Cohen NA, Garrick N, Karoum F, Wyatt RJ (1981): Biochemical indices of the effects of the selective MAO inhibitors clorgyline, pargyline and deprenyl in man. In Usdin E, Dahl SG, Gram LF, Ligjaerde O (eds), Clinical Pharmacology in Psychiatry Neuroleptic and Antidepressants Research. New York: Macmillan, pp 301-316
24. Murphy DL, Sims KB, Karoum F, Garrick NA, De La Chapelle A, Sankila EM, Norio R, Breakefield XO (1991): Plasma amine oxidase activities in Norrie disease patients with an X-Chromosomal deletion affecting monoamine oxidase. J Neural Transm Gen Sect 83:1-12
25. Pineda JA, Foote SL, Neville HJ (1989): Effects of locus coeruleus lesions on auditory, long-latency, event related potentials in monkeys. J Neurosci 9:429-432
26. Pliszka SR, McCracken JT, Maas JW (1996): Catecholamines in attention-deficit hyperactivity disorder: Current per-spectives. J Am Acad Child Adol Psychiatr 35:264-272
27. Rapoport JL, Lott I, Quinn PO, Scribanic N, Murphy DL (1974): Platelet serotonin of hyperactive school age boys. Br J Psychiatr 125:138-140
28. Reimherr FW, Wender PH, Ebert MH, Wood DR (1984): Cerebrospinal fluid homovanillic acid and 5-hydroxyindole acetic acid in adults with attention deficit hyperactivity disorder, residual type. Psychiatr Res 11:71-78
29. Sandler M (1982): Catecholamine synthesis and metabolism in man: Clinical implications (with special reference to parkinsonism). Catecholamines. In Blashko H, Muscholl E (eds), Handbook of Experimental Pharmacology, vol 33. Berlin, Springer-Verlag, pp 845-899
30. Segal M, Bloom FE (1976): The action of norepinephrine in the rat hippocampus: IV. The effects of locus coeruleus stimulation on evoked hippocampal unit activity. Brain Res 107:513-525
31. Shaywitz BA, Cohen DJ, Bowers MB (1977): CSF amine metabolites in children with minimal brain dysfunction. J Pediatr 90:67-71
32. Shekim WO, Dekirmenjian H, Chapel JL (1979): Urinary catecholamine MHPG excretion in minimal brain dysfunction and its modification by d-amphetamine. Am J Psychiatr 136:667-671
33. Shenker A (1992): The mechanism of drugs used to treat Attention-Deficit Hyperactivity Disorder: Focus on catecholamine receptor pharmacology. Adv Pediatr 39:337-382
34. Shetty T, Chase TN (1976): Central monoamines and hyperkinesis of childhood. Neurology 26:1000-1006
35. Soubrie P (1986): Reconciling the role of central serotonin neurons in human and animal behavior. Behav Brain Sci 9:319-364
36. Sunderland T, Cohen RM, Molchan S, Lawlor BA, Mellow AM, Newhouse PA, Tariot PN, Mueller EA, Murphy DL (1994): High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatr 51:607-612
37. Weizman A, Bernhout E, Weitz R, Tyano S, Rehavi M (1988): Imipramine binding of platelets of children with attention deficit hyperactivity disorder. Biol Psychiatr 23:491-496
38. Yu-Cun A, Yu-Feng W (1984): Urinary 3-methoxy-4-hydroxy-phenylglycol sulfate excretion in seventy-three school children with minimal brain dysfunction syndrome. Biol Psychiatr 19:861-870
39. Zametkin AJ, Rapoport JL (1987): Neurobiology of attention deficit disorder with hyperactivity: Where have we come in 50 years? J Am Acad Child Adol Psychiatr 5:676-686
40. Zametkin AJ, Brown GL, Karoum F, Rapoport JL, Langer DH, Chuang LW, Wyatt RJ (1984): Urinary Phenethylamine Response to d-Amphetamine in 12 Boys with Attention Deficit Disorder. Am J Psychiatr 141:9:1055-1058